Q-omics provides the consensus-scored HRH1 profile across patient tissues and cancer cell-line models. HRH1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HRH1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, HRH1 RNA expression shows 17,778 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where HRH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HRH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HRH1 survival associations across molecular data types. HRH1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HRH1 RNA expression–survival associations across cancer types. High HRH1 expression shows unfavorable associations in MESO, PAAD, LGG, LAML, LUSC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HRH1 RNA expression.
This table summarizes HRH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HRH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HRH1 shows lower tumor expression in UCEC and higher tumor expression in KIRC, THCA, KIRP, STAD and HNSC. The KIRC box plot shows higher HRH1 RNA expression in tumor versus normal tissue (log2 FC = +1.257, t-test p < 0.001).
This table shows molecular features associated with HRH1 in patient tissues and cancer cell lines. In patient samples, HRH1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HRH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
